Stocktoria
Unicycive Therapeutics, Inc. UNCY
Unicycive Therapeutics, Inc. (UNCY) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 0.49% (safety: no dividend).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.611 |
| Retained earnings / assets | -2.602 |
| EBIT / assets | -0.601 |
| Equity / liabilities | 1.595 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| UNCY | Unicycive Therapeutics, Inc. | 2/9 | -6.84 | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
FAQ
Is UNCY financially healthy?
Unicycive Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does UNCY pay a dividend, and is it safe?
Yes. Unicycive Therapeutics, Inc. pays a dividend yielding about 0.49% with a None payout ratio, rated “no dividend” for safety.
How profitable is UNCY?
In FY2025, Unicycive Therapeutics, Inc. had a return on equity of -87.9%.
What is the analyst price target for UNCY?
The average Wall-Street price target for Unicycive Therapeutics, Inc. is $41.30, about 666.2% above the recent price, from 10 analysts (consensus: strong buy).
Is UNCY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Unicycive Therapeutics, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone, a dividend yield of 0.49%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.